NCT03595592 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03595592
Title	Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer (APTneo)
Acronym	APTneo
Recruitment	Active, not recruiting
Gender	female
Phase	Phase III
Variant Requirements	No
Sponsors	Fondazione Michelangelo
Indications	Her2-receptor positive breast cancer
Therapies	Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab Atezolizumab + Carboplatin + Paclitaxel + Pertuzumab + Trastuzumab Atezolizumab + Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab
Age Groups:	senior \| adult
Covered Countries	ITA \| ESP \| DEU \| AUT

NCT03595592
Clinical Trial Detail